Clinical trial NCT00676260: Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treated With Insulin
Official title: Effect of Pioglitazone 15 mg or 30 mg on Microcirculation in Type 2 Diabetes Patients Treated With Insulin
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Diabetes Mellitus
Keywords: Glucose Metabolism Disorder
Dysmetabolic Syndrome
Type II Diabetes
Diabetes Mellitus
Lipoatrophic
Dyslipidemia
Drug Therapy
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2008-05-13
Enrollment: 29
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to measure microcirculation in type 2 diabetes patients with peripheral edema who are taking pioglitazone, once daily (QD).

Detailed description: Pioglitazone is a thiazolidinedione compound with a mode of action as a peroxisome proliferator-activated receptor gamma agonist. Activation of this receptor causes increased transcriptional activity at a number of locations that are important to carbohydrate and lipid (fat) metabolism. Insulin resistance is reversed by enhancing the action of insulin, thereby promoting glucose utilization in peripheral tissues, suppressing gluconeogenesis in the liver, and reducing lipolysis at the adipocyte.

In previous studies of pioglitazone, peripheral edema (swelling in the hands, feet, and legs) was reported as an adverse event more often in pioglitazone groups and appears to be a dose dependent phenomenon with pioglitazone. The incidence of peripheral edema in monotherapy studies was 3.2% in pioglitazone patients compared with 0.7% placebo patients and was reported more by females than males. This incidence was higher when pioglitazone was combined with sulphonylurea or insulin (5.9% and 15.6%, respectively). In comparison, the incidence of edema, when sulphonylurea or insulin was combined with placebo, was 2.1% and 7.5%, respectively.

This study is designed to identify the mechanisms underlying peripheral edema formation with pioglitazone in patients with Type 2 diabetes.

Individuals who participate in this study will provide written informed consent and will be required to commit to a screening visit and approximately 4 additional visits at the study center. Study participation is anticipated to be about 10 to 12 weeks (or approximately 3 months). Multiple procedures will occur at each visit which may include fasting, blood collection, urine collection, physical examinations and electrocardiograms.

Eligibility criteria: Inclusion Criteria:

* Stable glycemic control glycosylated hemoglobin between 6.5 and 10%) in the two months prior to the study.
* Type 2 diabetes treated by diet and stable dose of insulin (alone or with metformin) in the three months prior to the study.
* Female patients must have been postmenopausal, had a hysterectomy, or were surgically sterilized.

Exclusion Criteria:

* Has Type 1 diabetes.
* Has an episode of hypoglycemia requiring medical assistance three months prior to the study.
* Has peripheral artery disease (including Raynaud's syndrome) confirmed by an Ankle Brachial Pressure Index less than 0.9.
* Has severe chronic venous insufficiency as evidenced by venous ulceration or subcutaneous serum deposits.
* Has vascular autoimmune disease, had received a renal transplant, or were receiving dialysis.
* Has had heart failure (New York Heart Association I to IV), left ventricular hypertrophy evident from the ECG, or myocardial infarction 12 months prior to start of study.
* Has Subject had uncontrolled hypertension or familial polyposis coli.
* Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:

  * Non steroidal anti-inflammatory Drugs (except for aspirin at anti-aggregant doses), oral anti-diabetic drugs (except metformin), calcium-channel blockers, and diuretics at anti-edema doses are excluded from the study.
  * Treatment with systemic corticosteroids within four weeks prior to enrolment and during the study was not allowed.
  * Patients who have taken beta-blockers are to have been on a stable dose for four weeks before entry in the study.

Primary outcomes:
measure: Capillary filtration capacity.
timeFrame: Final Visit
Secondary outcomes:
measure: Isovolumetric venous pressure.
timeFrame: Final Visit
measure: Capillary pressure.
timeFrame: Final Visit
measure: Postural vasoconstriction.
timeFrame: Final Visit
measure: Maximum blood flow.
timeFrame: Final Visit
measure: Capillary recruitment.
timeFrame: Final Visit
measure: 24-hour ambulatory blood pressure.
timeFrame: Final Visit
measure: Interleukin-6
timeFrame: Final Visit
measure: C-Reactive Protein.
timeFrame: Final Visit
measure: Vascular Endothelium Growth Factor.
timeFrame: Final Visit
Other outcomes:
Locations:
city: Exeter
country: United Kingdom
Study officials:
affiliation: Takeda
name: Medical Director
role: STUDY_DIRECTOR
References:
citation: Tooke JE, Elston LM, Gooding KM, Ball CI, Mawson DM, Piper J, Sriraman R, Urquhart R, Shore AC. The insulin sensitiser pioglitazone does not influence skin microcirculatory function in patients with type 2 diabetes treated with insulin. Diabetologia. 2006 May;49(5):1064-70. doi: 10.1007/s00125-006-0168-9. Epub 2006 Mar 1.